Existing nasal drug delivery devices do a poor job of penetrating the nasal cavity to deposit drug onto the medial turbinates for systemic delivery. Such existing devices are also lacking in delivering drug to the upper nasal cavity for direct nose-to-brain delivery. Existing nasal drug delivery devices generate a wide plume which inadequately delivers a compound deep into the nasal cavity.
In one embodiment, a nozzle is described and claimed including a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form, the inlet disposed at the proximal end, a nozzle body defining two or more channels, the channels having a proximal and distal end, the body defining a longitudinal axis, and, an orifice disposed at the distal end of each channel.
In an aspect, the channels are disposed parallel to the longitudinal axis.
In another aspect, the channels are disposed at an angle with respect to the longitudinal axis.
In an aspect, the nozzle includes from five to seven channels.
In an aspect, the channels are circular and tubular in shape.
In an aspect, the channels are conical in shape.
In an aspect, four circular orifice apertures configured in a square orientation are disposed at the distal end of the nozzle.
In an aspect, five circular orifice configured in a pentagonal orientation are disposed at the distal end of the nozzle.
In an aspect, six circular orifice configured in a hexagonal configuration are disposed at the distal end of the nozzle.
In an aspect, six circular orifice configured in a centered pentagonal configuration are disposed at the distal end of the nozzle.
In an aspect, four circular orifice configured linearly are disposed at the distal end of the nozzle.
In an aspect, four rectangular orifice configured radially are disposed at the distal end of the nozzle.
In an aspect, five star-shaped orifice configured in a pentagonal configuration are disposed at the distal end of the nozzle.
In an aspect, the channels are plastic or metal tubes, the body is a plastic or metal tube, and, voids are disposed between the channels and body.
In another embodiment, a nozzle for delivering a compound to an upper olfactory region of a user is disclosed including a nozzle body having a central axis, a plurality of channels housed within the nozzle body, the channels having a proximal end and a distal end, an inlet disposed at the proximal end of the channel, an outlet orifice disposed at the distal end of the channel, the outlet orifice arranged parallel to the central axis of the nozzle.
In an aspect, a line drawn thru a point on the outlet orifice is an equal distance to the central axis of the nozzle.
In an aspect, the outlet orifices are arranged so that a narrow plume exits the nozzle.
In an aspect, the angle of the plume is about 5 degrees, about 4 degrees, about 3 degrees, about 2 degrees, about 1 degree.
In yet another aspect, the angle of the plume is about 5 degrees.
In an aspect, the impact force delivered by the nozzle is decreased.
In an aspect, the delivery time for the compound is decreased.
In another embodiment, a nozzle for delivering a compound to an upper olfactory region of a user is disclosed including a nozzle body, a compound channel housed within the nozzle body, the compound channel having a proximal end and a distal end, the proximal end capable of receiving a compound, the distal end of the compound channel having an outlet orifice, and a propellant channel, the propellant channel having a proximal end and a distal end, the proximal end capable of receiving a propellant, the distal end of the propellant channel having an outlet orifice, the compound channel being centered within the propellant channel wherein the compound and the propellant are capable of being emitted from the from outlet orifice.
In an aspect, the nozzle includes at least a second compound channel, wherein the nozzle is capable of delivering more than one compound at a time.
In another aspect, the compound delivered by the nozzle is a liquid, a powder, a gas, or combinations thereof.
In another aspect, the nozzle further includes a check shut off valve wherein the check shut off valve prevents propellant from flowing through the compound chamber once the compound is released.
Described herein are nozzles that deliver a compound into the posterior regions of the nasal cavity. Current nasal delivery systems do not adequately deposit drug in posterior regions of the nasal cavity such as the respiratory epithelium and olfactory region. Described herein are nozzles that enhance drug deposition into these regions of the nasal cavity.
The nozzles disclosed herein consistently deposit at least a majority fraction of dose into the distal parts of the nasal cavity such as the respiratory epithelium and olfactory region. A drug product (also referred to as drug formulation, intranasal dosage form and other like terms used in the art) is propelled with a velocity via the nozzle into the nasal cavity.
The nozzle may be used to deliver a compound to the upper olfactory region of a mammal or other animal. For instance, the user may be a human or non-human primate. The nozzle may have adult or pediatric users. In some aspects, the nozzle may be used in veterinary medicine. In some aspects, the nozzle may be used to deliver a therapeutic or palliative care compound.
Like named structures in the various embodiments function in the similar or same manner, are structurally the same or similar, and may be used in for the same or similar purpose.
A nozzle is disclosed with a plurality of outlet orifices for delivery of a compound. The nozzle has a central longitudinal axis. The nozzle houses a plurality of channels. The channels have a proximal end at which the compound to be delivered enters the channel and a distal end at which the compound exits the channel via an outlet orifice. In certain embodiments, the channels run parallel to the central axis of the nozzle. In other embodiments, the channels run substantially parallel to the central axis of the nozzle in that a line drawn thru a point on the outlet orifice is of equal distance to the central axis of the nozzle.
The outlet orifices are arranged in parallel alignment with the central axis of the nozzle. In one aspect, the outlet orifices are arranged where a line drawn through the orifice has an equal distance from a line drawn through the center of the nozzle. In yet another aspect, the arrangement of the outlet orifices of the nozzle provides a narrow plume. In yet a further aspect, the outlet orifices are arranged so that the initial path of the compound as it exits the nozzle is substantially parallel to the central axis of the nozzle. In yet another aspect, the outlet orifices are arranged in parallel alignment, in a line of equal distance from a center of the nozzle, in an arrangement that provides for the delivery of a narrow plume, in an arrangement that provides an initial path of the compound as it exits the nozzle substantially parallel to the central axis, or combinations thereof.
In an embodiment, the angle of the plume delivered from the nozzle is about 5 degrees, about 4 degrees, about 3 degrees, about 2 degrees, about 1 degree, inclusive of endpoints. In an embodiment, the angle of the plume delivered from the nozzle is about 5 degrees. In yet another embodiment, the angle of the plume is 5 degrees, is 4 degrees, is 3 degrees, is 2 degrees, or is 1 degree. In a further embodiment, the angle of the plume delivered from the nozzle is 5 degrees.
In embodiments of the nozzle, the impact force delivered by the nozzle having more than one outlet orifice is decreased.
In embodiments of the nozzle, the delivery time is decreased for delivery of a compound by a nozzle having more than one outlet orifice.
In another embodiment of the nozzle, the delivery time and the impact force is decreased by a nozzle having more than one outlet orifice.
In embodiments of the nozzle, the outlet orifices are arranged so that the propellant entrains the compound to be delivered. Without being bound by theory with regards to entrainment of the compound, the multiple streams exiting the nozzle created by the plurality of outlet orifices are better able to entrain air within the plume, thereby shielding the edges of the plume against friction induced turbulence at the edges of the plume.
As shown in
In one embodiment, the drug product inlet may be optional. In another embodiment, the nozzle has an attachment mechanism to the source of the compound being distributed from the nozzle. The attachment mechanism may be a screw, snap or other suitable mechanism. In another embodiment, the drug product inlet and nozzle may be of uniform construction with the chamber, container or the like holding the compound being delivered. When the drug product inlet is optional, a proximal end of the nozzle functions as the drug product inlet.
The channels may be circular, oval, square, triangular, parallelograms, trapezoidal or combinations thereof.
In one embodiment, the nozzle shown in
As shown in
As shown in
As shown in
As shown in
Shown in
In one embodiment, the outlet orifices are square, circular, oval, trapezoidal, parallelograms, triangular, star shaped, or combinations thereof.
In one embodiment, the nozzle shown in
In another embodiment, the nozzle shown in
Shown in
In one embodiment, the nozzle shown in
As shown in
In one embodiment, the nozzle shown in
As shown in
In one embodiment, the nozzle shown in
As shown in
Upon actuation of nozzle C, both chambers are pressurized and gas is emitted from the end of the nozzle as a uniform and symmetrical hollow cylinder, while at the same time the dose is emitted into the center of the gas cylinder. Depending on the configuration of the two channels and the amount and type of gas used to drive the nozzle, the relative velocity of the gas and powder streams can be different, causing different effects on performance. In one embodiment, multiple dose transport channels are placed in the center of the gas transport tube so that this nozzle design would deliver doses of more than one drug at the same time with minimal mixing before the drugs are deposited on the target surface or tissue.
In one embodiment, the drug channel can transport a liquid, a powder, a gas, or combinations thereof.
In one embodiment, a bypass nozzle D is shown as in
A variety of compounds may be delivered by the nozzle. In one embodiment, a mixture of drug and gas propellant is delivered by the nozzle. In another embodiment, a mixture of liquid propellant and drug is delivered by the nozzle. In another embodiment, a liquid propellant is delivered by the nozzle. In yet another embodiment, a drug is delivered by the nozzle. In yet other embodiments, a combination of compounds is delivered by the nozzle.
The compound delivered by the nozzle may be a liquid, gas, solid, or combinations thereof. The compound may be a liquid or a powder. The compound may be a drug.
The nozzle may be used to deliver compounds to many environments. The nozzle may be used to deliver a compound intranasally. The nozzle may be used to deliver a compound orally, rectally, vaginally, topically, to the eye, or intranasally.
The nozzle may be used to deliver medicaments or other compounds not for therapeutic use. For example, the nozzle may be used to deliver a precise plume in manufacturing.
Set forth below are examples of nozzles and outlet orifices.
In nozzle number 1, a five outlet nozzle was constructed of 30 gauge (G) stainless steel tubes, (approximately 0.0069 inch circular orifice and approximately 5 mm in length) mounted within a 20G stainless steel tube. The 30G tubes fit tightly and formed a symmetric pentagonal arrangement that would lie symmetrically on a circle. All non-orifice gaps between the individual 30G tubes were filled. The distal end of the nozzle was finished with all tubes flush and of equal length. The openings were finished clean and square.
Nozzle number 2 was constructed having 11 outlets composed of 5, 25G stainless tubes (approximately 0.011 inch circular orifice and approximately 5 mm in length) mounted within an 18G stainless steel tube for a tight fit. No voids between the 25G and 15G tubes were filled, so the nozzle configuration had 5 additional ports, approximately triangular in shape, the nozzle ports surrounding the 5 circular ports. In addition, a central void of roughly pentagonal shape exists at the very center which was capable of passing a dose. The distal end of the nozzle was finished with all tubes flush and of equal length. The openings were finished clean and square.
Nozzle number 3, as shown in
Nozzle number 10 has some of the same components used to assemble nozzle number 3. For nozzle number 10, each 23G stainless tube has an approximately 30 degree bend in the last 2 mm of the tube at the distal end of the nozzle. These tubes were inserted into a 14G stainless steel tube so that their orientation was all the same around the perimeter of the 14G tube. These were held in place with a central brass rod. The distal end of the nozzle was finished with all tubes flush and of equal length. The openings were finished clean and square. Because of the 30 degree bend in the 23G tubes, they are oval in dimensions and not round. All voids between elements were open.
Nozzle number 11 has some of the same components of nozzle number 9 (Example 3) with straight 23G stainless steel tubes set into a 14G stainless steel tube. No brass rod was used to hold the tubes in, with the 14G tube being lightly crimped. The distal end of the nozzle was finished with all tubes flush and of equal length. The openings were finished clean and square. All voids between elements were open.
Nozzle number 13 has some of the same components as nozzle number 2. Similar to nozzle number 1 (Example 1), nozzle number 13 has all intervening open voids filled leaving 5 active nozzle ports in the same special relationship as those in nozzle number 2.
Nozzle number 5 has four outlets of 30G stainless steel tubes in a linear arrangement within a modified 16G stainless steel tube. The 30G tubes were set by light crimping of the 16G tube and filler was applied to fill all voids between the 30G and 16G tubes. The distal end of the nozzle was finished with all tubes flush and of equal length. The openings were finished clean and square.
Nozzle number 12 has five outlets consisting of 27G stainless steel needle ends arranged with the pointed ends extending beyond the end of the nozzle housing (a 16G stainless steel tube). All five 27G needles were arranged so that the point was placed closest to the center of the assembly. The assembly of 5 needles was secured within the 16G tube under tension from a centrally placed brass rod. The brass rod was tapered so that a tension fit held everything together. All voids other than the 5 outlet ports were filled with epoxy prior to final assembly. The resulting nozzle had a tapered distal end that extended approximately 2.66 mm from the end of the 16G nozzle housing. All port surfaces were finished clean and square.
Nozzle 19 is a composite assembly of nozzle number 37 (Example 6) with 27G stainless steel needles inserted into the port channels of a nozzle number 37 nozzle assembly. The needles extend from the plastic end of the distal end of the nozzle by approximately 5.5 mm. The needles are all arranged so that the tip side of each needle is oriented toward the center of the nozzle. They lie closest to the central axis of the nozzle.
Nozzle number 14 has seven outlet ports arranged around a central aerodynamic extension, analogous to nozzle number 7 (Example 8 and
Nozzle number 15 is similar to nozzle number 14 but with the body of the section of the assembly before the nozzle proper being shorter while still including a female luer lock. Nozzle number 15 is cast entirely in plastic as a unit.
Nozzle number 16 has 4 outlet ports arranged approximately 0.7 mm apart and equidistant in a square pattern. Nozzle number 16 has a similar female luer lock design as for nozzle number 15 (Example 5). Port lumen lengths are approximately 5.3 mm in length, parallel to each other and on axis with the nozzle body. Cast entirely in plastic as a unit.
Nozzle number 37 is similar to nozzle number 16, except 5 outlet ports arranged equidistant to each other and as if placed on a circle or the apices of a pentagon. Port channel lengths are 5.3 mm and include the same luer lock as nozzle number 16. Cast entirely in plastic as a unit.
Nozzle number 38 has 4 outlet ports as in nozzle number 16. The port channels of nozzle number 38 traverse 10.3 mm and they possess a right handed twist (as viewed at the distal end) of approximately 180 degrees in that distance. The nozzle is longer than nozzle 16 and contains the same luer features and spatial details as nozzle 16. Cast entirely in plastic as a unit.
Nozzle number 4, as shown in
Nozzle number 7, as shown in
Nozzle number 8, as shown in
Nozzle number 9, as shown in
Nozzles for the delivery of a dry powdered dose.
The nozzles of this Example are shown in
Nozzle A. Single port nozzle. Several configurations of solid plastic drilled with a straight exit port of varying lengths were tested. A 4.45 mm diameter plastic nozzle with a single 1.07 mm internal diameter port of approximately 1 cm in length was tested. Also tested was a 4.45 mm in diameter nozzle with a single 0.67 mm internal diameter port of 8.75 mm in length. A third configuration was a nozzle of approximately 1 cm in length with a single nozzle port of 0.031 inch internal diameter. The powder is driven through the port tube by gas pressure.
Nozzle B. Multiple port nozzle. Drilled in PEEK plastic. 5 nozzle ports of internal diameter of 0.015 inch. Orifice diameters are 0.011 inches. The dose is driven through the multiple ports by gas pressure.
Nozzle C. Single port annular gas bypass nozzle. Two configurations were designed and tested. This nozzle design is a two compartment nozzle, one for the dose and one for gas. These nozzles feature a straight 0.031 in internal diameter port tube that transports the powder. This transport tube is centered inside of another tube that serves to deliver a stream of gas. The configurations tested have different gas tube diameters and therefore affect the amount and velocity of gas emitted from the end of the nozzle. Both the powder transport tube and the gas tubes can be altered to change the performance of the nozzle assembly. These test configurations were designed to be driven by a single source of compressed gas (e.g. hydrofluoroalkane), but each compartment of the nozzle could be independently driven. Upon actuation, both chambers are pressurized and gas is emitted from the end of the nozzle as a uniform and symmetrical hollow cylinder, while at the same time the dose is emitted into the center of the gas cylinder. Depending on the configuration of the two tubes and the amount and type of gas used to drive the nozzle, the relative velocity of the gas and powder streams can be different, causing different effects on performance.
The inner diameter of the dose tube is 0.031 in for all three nozzles. The zero (0) bypass nozzle is the third configuration described in A above. Low bypass nozzle has a gas tube gap of 0.008 in. The high bypass nozzle has a gas tube gap of 0.016 in.
Nozzle D. A variant of nozzle C was made and tested, shown in
Analytical Methods Employed for Nozzle Testing
Plume Geometry
Plume angle was tested as a performance criterion. The testing of the nozzles included establishing the angle of the plume and/or the size of the deposition area at a fixed distance from the nozzle tip.
1) Photography. The pattern of expelled high pressure water from the nozzle was photographed and the angle described by the pattern on the printed photo was measured. This method proved to be accurate and reproducible. Additional methods would look at describing the plume angle of an aerosolized plume as would be generated during actual use. Photography data was used as comparison data for the nozzles described herein.
2) Blotter paper deposition. A method was developed that relied on the deposition of a stained (Fluorescein) aqueous dose emitted from a nozzle onto a blotter paper held at a distance of 4 cm. 4 cm was chosen as a distance relevant to the distance needed to traverse from a likely nozzle tip position in the human naris to the upper olfactory region of the human nasal sinus. This blotter paper deposition assay offered the advantage of creating a permanent record of the dose deposition. In addition, it would be capable of showing any asymmetry in plume geometry. Plume angles were calculated using the blotter paper deposition. A limitation of this method is that the dose staining can bleed beyond the region of deposition, thereby making the observed deposition spot to be larger than the actual deposition zone. This is especially true for larger dose volumes and for nozzles that concentrate the dose into the smallest zone. Another limitation is that the method describes the end result of the deposition and cannot describe how deposition occurs over the course of the event. This limitation yields less information about the nature of the plume as it starts, progresses and ends. It can say very little about how the plume is affected by its travels through the air from nozzle to target.
Two additional approaches designed to analyze plume geometry during the time course of dose delivery were applied.
3) High speed blotter recording, with dose deposition onto a rapidly spinning blotter paper target. This method is able to create a physical record of deposition over time. The blotter disk can be rotated fast enough so that dose spread is reduced and appears to yield accurate plume geometries displayed during the full shot. It appears to be able to discriminate between different nozzle designs and can catch asymmetries in plume geometry.
4) The second method is high speed videography (greater than 200 frames per second) enhanced with fluorescent dye and lighting. This method appears capable of discriminating the performance between different nozzle designs and can record defects in performance. This method has been adapted for studying nozzle performance under various situations, such as free air performance and within human nasal models.
5) An adaptation of method high speed videography. Modified lighting conditions were used to enhance the visualization of powder doses. In some cases lighting was adjusted so that only limited sections of the spray plume were visible. White light illumination is valuable for seeing the overall plume geometry for powder, however white light is easily scattered and is not able to report on the various dose densities within a plume and likely best highlights the surface of a powder plume. Using single wavelength light in the red spectrum is able to reduce light scatter and better penetrate a powder plume.
Dose Deposition
Previous methods are principally directed at understanding plume geometry generated by each nozzle. We used these methods to attain certain pre-determined performance parameters, such as symmetrical and narrow plumes, to predict actual performance in use. An in vitro method for assessing nozzle performance was to measure dose deposition efficiency in human nasal models. We have employed several methods for this, differing mostly in the manner in which we quantitate the amount of dose deposited in different areas of the human nasal sinus. Of the three methods developed, here we report data generated from two methods.
5) One method assessed deposition by dose weight and was able to report only dose weight deposited in our upper olfactory region of interest (ROI) and elsewhere.
6) Another method reports dose deposition through optical densitometry. This method is capable of reporting fractional deposition within our upper olfactory ROI as well as any number of other ROI that are user defined.
Impact Force
Another physical performance characteristic that affected nozzle design was the impact force generated by the developed plume from any nozzle. We developed a method that records impact force profiles (including maximal impact force) for the duration of a dose shot. Forces generated during dosing could be compared to other commercially available nasal spray devices.
Results:
Plume Geometry:
Many of the nozzles described herein have principle deposition zone dimensions of 3 mm or less when fired 4 cm from the target with relatively minor amounts of dose outside of 5 mm. This represents a plume angle of about 5 degrees or under. It should be noted that the dimensions of the upper olfactory region of the human nasal sinus is on the order of several mm eventually narrowing down to 1-2 mm.
An early deposition study (method 5) along with a study with method 3 allowed a direct comparison between some of the nozzles described in this application with a nozzle designed to generate a rotating plume and also to a single port device (urethral tip).
As shown in Table 1, high speed blotter paper deposition analysis was carried out with each nozzle in this experiment with the exceptions of nozzle number 1 and the urethral tip. Later comparisons with nozzle number 1 revealed that nozzle number 1 is able to achieve the smallest deposition zone for any of the nozzles tested. The urethral tip is also able to achieve a deposition zone approaching that of nozzle number 13.
The deposition study presented in Table 1 shows the average from at least three nozzle firings for each nozzle and each aim angle. All conditions of firing were the same for all the nozzles and for each firing condition studied. A correlation can be made between the size of the dose deposition zone and the percent of dose deposited in the upper olfactory region of a human nasal model. The correlation persists regardless of the aim angle used for these shots. We conclude that the smaller the dose plume angle is, the higher the deposition in our ROI. Not expected from these results is that some of the nozzles appear to perform better regardless of the aim of the nozzle. In contrast, the urethral tip, which has a single nozzle port and generates a single plum stream, appears to be more sensitive to aim angle. While the urethral tip has good deposition (though by no means the best) when aimed directly at the target, its performance falls off dramatically at most other angles. We generally see with this data that multiport nozzles, which generate multiple stream plumes, perform better in off-angles compared to the single port nozzle.
The experimental results presented in the
Two measured parameters, nasal model deposition and plume stability, point to a parallel multistream nozzle configuration being better able to maintain a narrow dose plume while traveling to the target. Our results demonstrate a narrow plume can deposit on the narrow recessed upper olfactory region of the human nasal sinus. Also, a multistream dose plume appears to better negotiate the intricacies of the complex human sinus. The off-angle performance advantage for a multistream dose plume compared to the urethral catheter (e.g., a single port 0.020 inch nozzle) demonstrates that clearly. Without being bound by theory, it may be that the ability of a multistream dose plume's ability to entrain air (essentially forming an air capsule) is capable of solving both of these challenges (nasal model deposition and plume stability). Such an air capsule may reduce peripheral turbulent degradation of the dose steam as well as buffer its interaction with the walls of the nasal sinus.
Table 2 addresses the property of shot duration for various narrow plume nozzles. Multi port nozzles have the advantage of initiating and completing dose delivery in relatively short times. In contrast, the best performing single port nozzle (with respect to deposition zone) required in excess of 50 milliseconds to complete a reduced volume dose. The single port nozzles would greatly limit the size of the dose that a device could deliver. A 50 μL dose would take in excess of 100 milliseconds and a 100 μL dose nearly 2/10 ths of a second. This is too long for a user actuated device. Even if increasing the single port aperture to 0.020 in, which could in theory bring the shot duration performance into line with the multiport nozzles, performance is lost, as shown in Tables 1 &
Table 2 shows physical dimensions of spray plume and duration of spray for 4 parallel multiport nozzles and one single port nozzle.
Powder Nozzles
In contrast, the bypass nozzles do not possess this feature. The powder appears to be buffered against impact with any stationary air in the firing path. Without being bound by theory, we believe that the propellant that exits the nozzle has displaced the stationary air, replacing it with a forward moving stream of gas. This forward stream of gas likely paves the way or carries the powder as if on a slipstream moving in the direction aimed. Additional studies have shown what appears to be more tightly collimated powder streams when fired from the bypass nozzles, as shown in
Nozzle 18 was constructed of qty. five (5) metal tubes with an internal diameter of 0.01 inches and an external diameter of 0.02 inches contained within a 15 metal tube with an internal diameter of 0.054 inches and an external diameter of 0.070 inches. The metal tubes are frictionally secured. Air gaps are disposed between the needles. Nozzle 18 is illustrated in
Nozzle 35b included five (5) outlet orifices with a diameter of 0.008 inches which extend out from the housing body and terminate as sharp points. Nozzle 35b is illustrated in
Nozzle 31 included qty. seven (7) outlet orifices with diameter of 0.015 inches. Nozzle 31 is illustrated in
Nozzle 33 included qty. five (5) outlet orifices each with a diameter of 0.015 inches. The outlet orifices on the distal end of Nozzle 33 are illustrated in
Nozzle 17 was constructed with five outlet orifices with a diameter of 0.006 inches. The outlet orifices on the distal end of Nozzle 17 are illustrated in
Set forth in Table 3 is data generated using various nozzles in accordance with the invention.
Average deposition was done with the nozzle aimed at optimal orientation into a human nasal sinus model. Depositions were determined by dose weights deposited onto model surfaces with the average of a minimum of three experiments.
Spray plume diameter and Average impact force measurements were taken with nozzles positioned at 4 cm distant from recording device. Outlet orifice diameter is by direct measurement.
This application is a continuation of an international patent application PCT/US12/37132, filed May 9, 2012, which claims priority from U.S. Provisional Application Ser. No. 61/484,048, filed May 9, 2011, which applications are hereby incorporated by reference herein in their entirety.
The instant invention was made with U.S. government funding pursuant to US Army SBIR grant W81XWH-10-C-0238. The Government may have certain rights in this application.
Number | Name | Date | Kind |
---|---|---|---|
2933259 | Raskin | Apr 1960 | A |
3425414 | Laroche | Feb 1969 | A |
3767125 | Gehres | Oct 1973 | A |
3888253 | Wall et al. | Jun 1975 | A |
3906950 | Cocozza | Sep 1975 | A |
3908654 | Lhoest et al. | Sep 1975 | A |
3921637 | Bennie et al. | Nov 1975 | A |
3949939 | Brown | Apr 1976 | A |
3971377 | Damani | Jul 1976 | A |
3998226 | Harris | Dec 1976 | A |
4095596 | Grayson | Jun 1978 | A |
4187985 | Goth | Feb 1980 | A |
4227522 | Carris | Oct 1980 | A |
4338931 | Cavazza | Jul 1982 | A |
4353365 | Hallworth et al. | Oct 1982 | A |
4412573 | Zdeb | Nov 1983 | A |
4446990 | Stevenson et al. | May 1984 | A |
4620670 | Hughes | Nov 1986 | A |
4702415 | Hughes | Oct 1987 | A |
4896832 | Howlett | Jan 1990 | A |
4995385 | Valentini et al. | Feb 1991 | A |
5170942 | Spink et al. | Dec 1992 | A |
5224471 | Marelli et al. | Jul 1993 | A |
5307953 | Regan | May 1994 | A |
5331954 | Rex et al. | Jul 1994 | A |
5349947 | Newhouse et al. | Sep 1994 | A |
5382236 | Otto et al. | Jan 1995 | A |
5398850 | Sancoff et al. | Mar 1995 | A |
5435282 | Haber et al. | Jul 1995 | A |
5505193 | Ballini et al. | Apr 1996 | A |
5516006 | Meshberg | May 1996 | A |
5690256 | Smith | Nov 1997 | A |
5711488 | Lund | Jan 1998 | A |
5715811 | Ohki et al. | Feb 1998 | A |
5797390 | McSoley | Aug 1998 | A |
5814020 | Gross | Sep 1998 | A |
5819730 | Stone et al. | Oct 1998 | A |
5823183 | Casper et al. | Oct 1998 | A |
5875776 | Vaghefi | Mar 1999 | A |
5881719 | Gottenauer et al. | Mar 1999 | A |
5901703 | Ohki et al. | May 1999 | A |
5906198 | Flickinger | May 1999 | A |
5910301 | Farr et al. | Jun 1999 | A |
5954696 | Ryan | Sep 1999 | A |
6062213 | Fuisz et al. | May 2000 | A |
6092522 | Calvert et al. | Jul 2000 | A |
6145703 | Opperman | Nov 2000 | A |
6158676 | Hughes | Dec 2000 | A |
6180603 | Frey, II | Jan 2001 | B1 |
6186141 | Pike et al. | Feb 2001 | B1 |
6189739 | von Schuckmann | Feb 2001 | B1 |
6294153 | Modi | Sep 2001 | B1 |
6302101 | Py | Oct 2001 | B1 |
6313093 | Frey, II | Nov 2001 | B1 |
6347789 | Rock | Feb 2002 | B1 |
6367471 | Genosar et al. | Apr 2002 | B1 |
6367473 | Kafer | Apr 2002 | B1 |
6382465 | Greiner-Perth | May 2002 | B1 |
6410046 | Lermer | Jun 2002 | B1 |
6418925 | Genova et al. | Jul 2002 | B1 |
6491940 | Levin | Dec 2002 | B1 |
6540983 | Adjei et al. | Apr 2003 | B1 |
6569463 | Patel et al. | May 2003 | B2 |
6585172 | Arghyris | Jul 2003 | B2 |
6585957 | Adjei et al. | Jul 2003 | B1 |
6585958 | Keller et al. | Jul 2003 | B1 |
6595202 | Ganan-Calvo | Jul 2003 | B2 |
6622721 | Vedrine et al. | Sep 2003 | B2 |
6644305 | MacRae et al. | Nov 2003 | B2 |
6644309 | Casper et al. | Nov 2003 | B2 |
6647980 | Gizurarson | Nov 2003 | B1 |
6681767 | Patton et al. | Jan 2004 | B1 |
6684879 | Coffee et al. | Feb 2004 | B1 |
6701916 | Mezzoli | Mar 2004 | B2 |
6715485 | Djupesland | Apr 2004 | B1 |
6729334 | Baran | May 2004 | B1 |
6734162 | Van Antwerp et al. | May 2004 | B2 |
6810872 | Ohki et al. | Nov 2004 | B1 |
6923988 | Patel et al. | Aug 2005 | B2 |
6991785 | Frey, II | Jan 2006 | B2 |
7033598 | Lemer | Apr 2006 | B2 |
7051734 | Casper et al. | May 2006 | B2 |
7063686 | Mezzoli | Jun 2006 | B2 |
7163013 | Harrison | Jan 2007 | B2 |
7182277 | Vedrine et al. | Feb 2007 | B2 |
7200432 | Lemer et al. | Apr 2007 | B2 |
7214209 | Mazzoni | May 2007 | B2 |
7231919 | Giroux | Jun 2007 | B2 |
7258119 | Mazzoni | Aug 2007 | B2 |
7296566 | Alchas | Nov 2007 | B2 |
7347201 | Djupesland | Mar 2008 | B2 |
7377901 | Djupesland et al. | May 2008 | B2 |
7476689 | Santus et al. | Jan 2009 | B2 |
7481218 | Djupesland | Jan 2009 | B2 |
7543581 | Djupesland | Jun 2009 | B2 |
7655619 | During et al. | Feb 2010 | B2 |
7740014 | Djupesland | Jun 2010 | B2 |
7784460 | Djupesland et al. | Aug 2010 | B2 |
7799337 | Levin | Sep 2010 | B2 |
7819342 | Spallek et al. | Oct 2010 | B2 |
7832394 | Schechter et al. | Nov 2010 | B2 |
7841337 | Djupesland | Nov 2010 | B2 |
7841338 | Dunne et al. | Nov 2010 | B2 |
7854227 | Djupesland | Dec 2010 | B2 |
7866316 | Giroux | Jan 2011 | B2 |
7875001 | Minotti | Jan 2011 | B2 |
7905229 | Giroux et al. | Mar 2011 | B2 |
7934503 | Djupesland et al. | May 2011 | B2 |
7975690 | Djupesland | Jul 2011 | B2 |
7994197 | Cook et al. | Aug 2011 | B2 |
8001963 | Giroux | Aug 2011 | B2 |
8047202 | Djupesland | Nov 2011 | B2 |
8119639 | Cook et al. | Feb 2012 | B2 |
8122881 | Giroux | Feb 2012 | B2 |
8146589 | Djupesland | Apr 2012 | B2 |
8171929 | Djupesland et al. | May 2012 | B2 |
8327844 | Djupesland | Dec 2012 | B2 |
8408427 | Wong | Apr 2013 | B2 |
8448637 | Giroux | May 2013 | B2 |
8511303 | Djupesland | Aug 2013 | B2 |
8517026 | Amon | Aug 2013 | B2 |
8522778 | Djupesland | Sep 2013 | B2 |
8550073 | Djupesland | Oct 2013 | B2 |
8555877 | Djupesland | Oct 2013 | B2 |
8555878 | Djupesland | Oct 2013 | B2 |
8596278 | Djupesland | Dec 2013 | B2 |
8733342 | Giroux et al. | May 2014 | B2 |
8757146 | Hoekman et al. | Jun 2014 | B2 |
8800555 | Djupesland | Aug 2014 | B2 |
8839790 | Beck Arnon | Sep 2014 | B2 |
8875794 | Carlsen et al. | Nov 2014 | B2 |
8899229 | Djupesland et al. | Dec 2014 | B2 |
8899230 | Immel | Dec 2014 | B2 |
8910629 | Djupesland et al. | Dec 2014 | B2 |
8925544 | Flickinger | Jan 2015 | B2 |
8978647 | Djupesland et al. | Mar 2015 | B2 |
8987199 | Abdel Maksoud et al. | Mar 2015 | B2 |
9010325 | Djupesland et al. | Apr 2015 | B2 |
9038630 | Djupesland et al. | May 2015 | B2 |
9067034 | Djupesland et al. | Jun 2015 | B2 |
9072857 | Djupesland | Jul 2015 | B2 |
9101539 | Nagata et al. | Aug 2015 | B2 |
9119932 | Djupesland | Sep 2015 | B2 |
9180264 | Young et al. | Nov 2015 | B2 |
9272104 | Djupesland | Mar 2016 | B2 |
9446207 | Jung | Sep 2016 | B2 |
20020017294 | Py | Feb 2002 | A1 |
20020054856 | Jones | May 2002 | A1 |
20020092520 | Casper et al. | Jul 2002 | A1 |
20020132803 | Dedhiya | Sep 2002 | A1 |
20030017119 | Rabinowitz et al. | Jan 2003 | A1 |
20030158527 | Mezzoli | Aug 2003 | A1 |
20030217748 | Giroux | Nov 2003 | A1 |
20040025866 | Vedrine et al. | Feb 2004 | A1 |
20040068222 | Brian | Apr 2004 | A1 |
20040094146 | Schiewe et al. | May 2004 | A1 |
20040238574 | Merk et al. | Dec 2004 | A1 |
20050023376 | Anderson | Feb 2005 | A1 |
20050028812 | Djupesland | Feb 2005 | A1 |
20050036985 | Ensoli | Feb 2005 | A1 |
20050098172 | Anderson | May 2005 | A1 |
20050142072 | Birch et al. | Jun 2005 | A1 |
20050274378 | Bonney et al. | Dec 2005 | A1 |
20060107957 | Djupesland | May 2006 | A1 |
20060219813 | Morrison | Oct 2006 | A1 |
20060240092 | Breitenkamp et al. | Oct 2006 | A1 |
20060260608 | Armstrong et al. | Nov 2006 | A1 |
20070056585 | Davies et al. | Mar 2007 | A1 |
20070068514 | Giroux | Mar 2007 | A1 |
20070074722 | Giroux et al. | Apr 2007 | A1 |
20070119451 | Wang et al. | May 2007 | A1 |
20070131224 | Giroux | Jun 2007 | A1 |
20070172517 | Ben-Sasson et al. | Jul 2007 | A1 |
20070202051 | Schuschnig | Aug 2007 | A1 |
20080054099 | Giroux et al. | Mar 2008 | A1 |
20080163874 | Djupesland | Jul 2008 | A1 |
20080178871 | Genova et al. | Jul 2008 | A1 |
20080230053 | Kraft | Sep 2008 | A1 |
20080305077 | Frey, II et al. | Dec 2008 | A1 |
20090320832 | Djupestand | Dec 2009 | A1 |
20100074959 | Hansom et al. | Mar 2010 | A1 |
20100218759 | Anderson et al. | Sep 2010 | A1 |
20110045088 | Tsutsui et al. | Feb 2011 | A1 |
20110048414 | Hoekman et al. | Mar 2011 | A1 |
20110053859 | Deadwyler et al. | Mar 2011 | A1 |
20120195959 | Ishii | Aug 2012 | A1 |
20120222675 | Dunne et al. | Sep 2012 | A1 |
20140170220 | Cartt et al. | Jun 2014 | A1 |
20140343494 | Hoekman et al. | Nov 2014 | A1 |
20150057287 | Cook et al. | Feb 2015 | A1 |
20150216823 | Chatterjee | Aug 2015 | A1 |
20150258178 | Gong | Sep 2015 | A1 |
20160101245 | Hoekman et al. | Apr 2016 | A1 |
20160228433 | Haruta et al. | Aug 2016 | A1 |
Number | Date | Country |
---|---|---|
1293580 | May 2001 | CN |
1930054 | Mar 2007 | CN |
101528358 | Sep 2009 | CN |
19518580 | Nov 1996 | DE |
102013100473 | Jul 2014 | DE |
0692273 | Jan 1996 | EP |
1165044 | Jan 2002 | EP |
806284 | Dec 1958 | GB |
1517642 | Jul 1978 | GB |
838607 | Feb 1996 | JP |
H08280808 | Oct 1996 | JP |
H08322934 | Dec 1996 | JP |
H09135901 | May 1997 | JP |
H09248342 | Sep 1997 | JP |
2000217919 | Aug 2000 | JP |
2005537834 | Dec 2005 | JP |
2007535352 | Dec 2007 | JP |
2010501227 | Jan 2010 | JP |
2010501228 | Jan 2010 | JP |
2011511674 | Apr 2011 | JP |
WO8601731 | Mar 1986 | WO |
WO9629044 | Sep 1996 | WO |
WO9913930 | Mar 1999 | WO |
WO0054887 | Sep 2000 | WO |
WO0136033 | May 2001 | WO |
WO0209707 | Feb 2002 | WO |
WO2007012853 | Feb 2007 | WO |
WO2008059385 | May 2008 | WO |
WO2009100383 | Aug 2009 | WO |
WO2012072542 | Jun 2012 | WO |
WO2012119153 | Sep 2012 | WO |
Entry |
---|
Spraying Systems, “Technical Reference” Jun. 25th, 2006, p. A5. |
The PCT Search Report and Written Opinion dated Jul. 26, 2012 for PCT application No. PCT/US12/37132, 9 pages. |
PCT Application PCT/US11/48435, filed on Aug. 19, 2011, Hoekman et al, Circumferential Aerosol Device for Delivering Drugs to Olfactory Epithelium and Brain. |
The Extended EP Search Report dated Nov. 28, 2014 for European patent application No. 12781605.6, 10 pages. |
The PCT Search Report and Written Opinion dated Aug. 14, 2014 for PCT application No. PCT/US14/35711, 13 pages. |
Translated Chinese Office Action dated Sep. 9, 2015 for Chinese patent application No. 201280029975.6, a counterpart foreign application of U.S. Appl. No. 14/075,126, 39 pages. |
Banks, et al., “Brain Uptake of the Glucagon-Like Peptide-1 Antagonist Exendin(9-39) After Intranasal Administration”, J. Pharmacol. Exp. Ther., 2004, vol. 309 (2), pp. 469-475. |
Translated Chinese Office Action dated May 24, 2016 for Chinese patent application No. 21280029975.6, a counterpart foreign application of U.S. Appl. No. 14/075,126, 38 pages. |
Ding, et al., “Olfactory Mucosa: Composition, Enzymatic Localization, and Metabolism”, Handbook of Olfaction and Gustation, 2nd Ed (Doty RL, Ed), 2003, pp. 51-73. |
Guo, et al., “Evaluation of Impaction Force of Nasal Sprays and Metered-Dose Inhalers Using the Texture Analyser”, J. Pharm. Sci., 2009, vol. 98 (8), pp. 2799-2806. |
Henry, et al., “A Pharmacokinetic Study of Midazolam in Dogs: Nasal Drop vs. Atomizer Administration”, Pediatr. Dent, 1998, vol. 20 (5), pp. 321-326. |
Translated Japanese Office Action dated Apr. 5, 2016 for Japanese Patent Application No. 2014-510444, a counterpart foreign application of U.S. Appl. No. 14/075,126, 25 pages. |
Letrent, et al., “Effects of a Potent and Specific P-Glycoprotein Inhibitor on the Blood-Brain Barrier Distribution and Antinociceptive Effect of Morphine in the Rat”, Drug Metab. Dispos., 1991, vol. 27 (7), pp. 827-834. |
Liu, et al., “Creation of a Standardized Geometry of the Human Nasal Cavity”, J. Appl. Physiol., 2009, vol. 106 (3), pp. 784-795. |
Mathison, et al., “Nasal Route for Direct Delivery of Solutes to the Central Nervous System: Fact or Fiction?”, J. Drug Target, 1998, vol. 5 (6), pp. 415-441. |
Morrison, et al., “Morphology of the Human Olfactory Epithelium”, J. Comp. Neurol., 1990, vol. 297 (1), pp. 1-13. |
Pardridge, “Targeting Neurotherapeutic Agents through the Blood-Brain Barrier”, Arch. Neurol., 2002, vol. 59 (1), pp. 35-40. |
Pardridge, “The Blood-Brain Barrier: Bottleneck in Brain Drug Development”, NeuroRx., 2005, vol. 2 (1), pp. 3-14. |
Pardridge, “The Blood-Brain Barrier and Neurotherapeutics”, NeuroRx., 2005, vol. 2 (1), pp. 1-2. |
Petroianu, et al., “New K-Oximes (K-27 and K-48) in Comparison with Obidoxime (LuH-6), HI-6, Trimedoxime (TMB-4), and Pralidoxime (2-PAM): Survival in Rats Exposed IP to the Organophosphate Paraoxon”, Toxicol. Mech. Methods, 2007, vol. 17 (7), pp. 401-408. |
Translated Russian Office Action dated Apr. 26, 2016 for Russian Patent Application No. 2013154420, a counterpart foreign application of U.S. Appl. No. 14/075,126, 6 pages. |
Sakane, et al., “Transport of Cephalexin to the Cerebrospinal Fluid Directly from the Nasal Cavity”, J. Pharm. Pharmacol., 1991, vol. 43 (6), pp. 449-451. |
Thiermann, et al., “Pharmacokinetics of Obidoxime in Patients Poisoned with Organophosphorus Compounds” Toxicol. Lett., 2010, vol. 197 (3), pp. 236-242. |
Zhang et al., “Preparation of Nimodipine-Loaded Microemulsion for Intranasal Delivery and Evaluation on the Targeting Efficiency to the Brain”, Int. J. Pharm., 2004, vol. 275 (1-2), pp. 85-96. |
Appasaheb, et al., “Review on Intranasal Drug Delilvery System”, Journal of Advanced Pharmacy Education and Research, vol. 3, Issue 4, Oct. 2013, 14 pages. |
The Australian Office Action dated Jan. 23, 2017 for Australian patent application No. 2012253569, a counterpart foreign application of U.S. Appl. No. 14/075,126, 3 pages. |
Baron, “Orally Inhaled Dihydroergotamine; Reviving and Improving a Classic”, Future Neurology, May 2011, 11 pages. |
Translated Chinese Office Action dated Jan. 18, 2017 for Chinese Patent Application No. 21280029975.6, a counterpart foreign application of U.S. Appl. No. 14/075,126, 6 pages. |
Constantino, et al., “Intranasal administration of acetylcholinesterase inhibitors”, BMC Neuroscience, Dec. 10, 2008, 3 pages. |
EP Ofice Action for 14727320.5, dated Nov. 9, 2016, 6 pages. |
EP Search Report for 09707800.0 dated Jul. 1, 2015, 12 pages. |
EP Search Report for 11818832.5 dated Sep. 24, 2014, 6 pages. |
Hanson, et al., “Intranasal delivery of growth differentiation factor 5 to the central nervous system”, Drug Delivery, 19(3):149-54, Feb. 2012, 7 pages. |
Hoekman, J.D., “The Impact of Enhanced Olfactory Deposition and Retention on Direct Nose-to-Brain Drug Delivery”, UMI Dissertation Publishing, Apr. 11, 2011, 181 pages. |
International Search Report for PCT/US/2009/033468 dated Dec. 2, 2009, 5 pages. |
Kumar, et al., “Nasal Drug Delivery: A Potential Route for Brain Targeting” The Pharma Innovation Journal, vol. 2, No. 1, Mar. 2013. 9 pages. |
Ozsoy, et al., “Nasal Delivery of High Molecular Weight Drugs”, Molecules Journal, Sep. 23, 2009, 26 pages. |
Parvathi, “Intranasal Drug Delivery to Brain: An Overview,” published in the International Journal of Research in Pharmacy and Chemistry 2012, 2(3), 7 pages. |
The PCT Search Report and Written Opinion dated Mar. 27, 2012 for PCT application No. PCT/US11/48435, 14 pages. |
Renner, et al., “Intranasal delivery of growth differentiation factor 5 to the central nervous system,” Drug Delivery, Feb. 2012, 7 pages. |
Translated Russian Office Action dated Aug. 18, 2016 for Russian patent application No. 2013154420, a counterpart foreign application of U.S. Appl. No. 14/075,126, 6 pages. |
Stevens, et al., “Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration”, in “Drug Metabolism and Disposition”, The American Society for Pharmacology and Experimental Therapeutics, vol. 39, No. 12, 8 pages. |
Talegaonkar, et al., “Intranasal delivery: an approach to bypass the blook brain barrier”, Indian J Pharmacol, Jun. 2004, vol. 36, Issue 3, 8 pages. |
Westin et al, “Direct Nose to Brain Transfer of Morphine After Nasal Administration to Rats”, Pharmaceutical Research, vol. 23, No. 3, Mar. 2006, 8 pgs. |
Westin, “Olfactory Tranfser of Analgesic Drugs After Nasal Administration”, Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 55, May 11, 2007, 66 pages. |
Yamada, et al., “Nose-to-brain delivery of TS-002, prostaglandin D2 analogue”, Journal of Drug Targeting, Jan. 2007, 9 pages. |
Yiman, et al., “Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors”, Cancer Letters 244(2), Dec. 2006, 9 pages. |
Ying, “The nose may help the brain: intranasal drug delivery for treating neurological diseases” Future Medecine, 3(1), Jan. 2008, 4 pages. |
Zhang, et al, “The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats”, Journal of Drug Targeting, Jun. 2006, 11 pages. |
Translated Japanese Office Action dated Mar. 28, 2017 for Japanese patent application No. 2014-510444, a counterpart foreign application of U.S. Appl. No. 14/075,126, 7 pages. |
The Japanese Reexamination Report dated Aug. 29, 2017 for Japanese patent application No. 2014-51044.4, a counterpart foreign application of U.S. Appl. No. 14/075,126, 6 pages. |
The European Office Action dated Aug. 16, 2017 for European patent application No. 12781605.6, a counterpart foreign application of U.S. Appl. No. 14/075,126, 5 pages. |
The Australian Office Action dated Dec. 4, 2017 for Australian patent application No. 2012253569, a counterpart foreign application of U.S. Appl. No. 14/075,126, 5 pages. |
Number | Date | Country | |
---|---|---|---|
20140083424 A1 | Mar 2014 | US |
Number | Date | Country | |
---|---|---|---|
61484048 | May 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US2012/037132 | May 2012 | US |
Child | 14075126 | US |